US FDA Approves Ionis-AstraZeneca To Treat Rare Nerve Disease hngn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hngn.com Daily Mail and Mail on Sunday newspapers.
Health News Roundup: US FDA approves Ionis-AstraZeneca's nerve disease drug; Cuba quietly authorizes euthanasia and more devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.
Operator: Greetings and welcome to the Arcturus Therapeutics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Biogen said it now expects full-year adjusted profit of $14.50 to $15.00 per share, the new high end of the range matching the low end of its previous forecast of $15 to $16